Godrej Agrovet Ltd

Q1 FY26Food Products

Godrej Agrovet Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹575

Market cap₹11.2K Cr

P/E23.8

Updated23 Aug 2026

Read4 min read

The short version

Overall top-line growth for FY '26 is expected in the early teens, with a 16%-18% growth guidance maintained. Top-line growth for Godrej Agrovet Limited (GAVL) expected in early teens for FY '26 with profit growth maintained as per Q1 FY '26. - Astec LifeSciences aims for EBITDA break-even in FY '26, targeting Rs.

From Godrej Agrovet Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Overall top-line growth for FY '26 is expected in the early teens, with a 16%-18% growth guidance maintained. (Page 5)
Crop protection standalone revenue growth is uncertain currently due to poor Hitweed product performance; better clarity expected after 3-4 weeks. (Page 15)
Astec LifeSciences aims for EBITDA break-even in FY '26, targeting Rs. 500 crore turnover with CDMO and new products growing over 30% annually beyond FY '26. (Pages 6, 13-14)
CDMO business revenue target is over Rs. 300 crore in FY '26, making up 65% of total sales. (Page 13)
Ashitaka herbicide has a theoretical market potential of about Rs. 200 crore over 3-4 years, with corn acreage growth supporting this. (Page 6)
Oil palm Fresh Fruit Bunch (FFB) arrivals are expected to grow 15%-18% in FY '26; oil extraction ratio (OER) expected better than FY '25's 19%. (Page 15)
Dairy segment aims to increase value-added product share to 50% in two years, improving EBITDA margins. (Page 12)

Profitability & Margins

Top-line growth for Godrej Agrovet Limited (GAVL) expected in early teens for FY '26 with profit growth maintained as per Q1 FY '26.
Astec LifeSciences aims for EBITDA break-even in FY '26, targeting Rs. 500 crores turnover; CDMO business expected to grow over 30% annually beyond FY '26.
Oil extraction ratio (OER) in palm oil segment expected to improve 15%-18% in FY '26, supporting profitability.
Dairy segment EBITDA margins targeted at 6%-7% for FY '26 despite increased ad spends, with value-added product share expected to rise.
Crop protection margins under pressure but expected to stabilize; new product launches (e.g., Ashitaka) anticipated to drive growth.
Overall consolidated profit growth was 25% in Q1 FY '26 over last year, indicating strong earnings momentum.

See what Godrej Agrovet Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Significant investments made recently include close to Rs. 1,250 crores in the last six months for buying out partners in Godrej Foods and Creamline Dairy to achieve 100% ownership, enabling cleaner portfolio decisions (Page 12).
Refitting of old plants for commercializing new CDMO products is planned; current new projects will be based on existing old plants with multipurpose capabilities allowing adjustments and refitting as needed (Page 13).
Mention of CapEx in last 2-3 years involving new plants to support CDMO products signifies ongoing capacity-building investments (Page 13).
No explicit future capex figures or timelines disclosed; growth in CDMO business and new product launches imply continued strategic investments.

Top-ranked in Food Products

Ranked on what management guided this quarter

5x potential

1Nurture Well Industries Ltd₹489 Cr

Rev 1Mar 1

2HOACFOODS₹439 Cr

Rev 1Mar 1

3₹1.2K Cr

Rev 1Mar 3

4₹205 Cr

Rev 1Mar 3

5₹595 Cr

Rev 2Mar 1

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The recent rights issue proceeds for Astec LifeSciences are being utilized primarily for debt repayment, as mentioned by S. Varadaraj.
There is no explicit mention of any new or planned fundraising through debt or equity in the current transcript.
The company appears focused on strategic clean-up of ownership, such as fully acquiring Godrej Foods and Creamline Dairy, funded by past investments (~Rs. 1,250 crores), rather than fresh fundraising.
Any future capital requirements or fundraising plans beyond this are not detailed in this call.
Management emphasizes growth and margin improvement funded through operational improvements and internal resources rather than new external fundraising at present.

See what Godrej Agrovet Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided does not contain specific details on the current or expected order book or pending orders for Godrej Agrovet Limited. The discussion primarily focuses on: - Financial performance and outlook for FY '26 - FFB arrivals and oil extraction ratios in FY '25 and expectations for FY '26 - Crop protection business performance and outlook - Value-added product focus in various segments - CDMO business traction and outlook - No explicit mention of order book status or pending orders in the transcript. If you need detailed order book information, it might be available in other company filings or investor presentations not included here.

Godrej Agrovet Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹2.3K Cr, net profit ₹102 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Godrej Agrovet's management said in earlier quarters

Others in Food Products this season

Hatsun Agro Product Ltd (Q1 FY26)
The impact of GST rate reduction on dairy products from 12% to 5%. Key concall takeaways from Hatsun Agro Product Ltd's Q1 FY26 earnings call — and how it…
Chatha Foods Ltd (Q1 FY26)
QSR client volumes are growing; Jubilant sees 20% year-on-year volume increase despite some customers shifting to in-house production. Key concall takeaways…
Gopal Snacks (Q1 FY26)
10 crores delta are observed. Key concall takeaways from Gopal Snacks Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Bikaji Foods (Q1 FY26)
Close to 6% organic volume growth excluding acquisitions. Key concall takeaways from Bikaji Foods International Ltd's Q1 FY26 earnings call — and how it ranks…

Compare:vs Nestle India vs Britannia Inds.vs Hatsun Agro Product Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Godrej Agrovet Ltd Q1 FY26 results?

What is Godrej Agrovet Ltd share price analysis?

Godrej Agrovet Ltd currently shows a neutral. The stock trades at a P/E of 23.8 with a market cap of ₹11,166 Cr. Investors should review the full earnings analysis for detailed insights.

Is Godrej Agrovet Ltd planning capital expenditure?

Significant investments made recently include close to Rs.

Keep Godrej Agrovet Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.